Liberisan (Cytisinicline)

Cytisinicline acts as a partial agonist at the α4β2 nicotinic acetylcholine receptors in the brain. This partial activation eases withdrawal while blocking nicotine’s full stimulation of the same receptors, thereby lowering cravings and the pleasure associated with smoking.

The specific dose and dosing schedule of Liberisan are determined by the prescribing healthcare professional based on individual patient needs, treatment goals, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for cytisinicline in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing Liberisan to pregnant or nursing individuals, and discuss alternative cessation strategies when appropriate.

To request Liberisan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike nicotine replacement products that supply nicotine, cytisinicline targets the nicotinic receptor directly as a partial agonist, offering a non‑nicotine approach. Compared with full agonists like varenicline, cytisinicline may produce fewer intense receptor stimulations, potentially resulting in a different side‑effect profile.

Liberisan should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Liberisan is taken orally, typically as a tablet swallowed with water. The exact timing relative to meals and other medications should follow the prescribing clinician’s guidance to ensure optimal absorption and effectiveness.

Serious risks, though rare, include mood alterations such as depression or suicidal thoughts, severe allergic reactions (rash, swelling, breathing difficulty), and cardiovascular events like hypertension or arrhythmia. Patients should seek immediate medical attention if any of these occur.

Liberisan is contraindicated in individuals with known hypersensitivity to cytisinicline or any tablet excipients. Caution is advised for patients with significant cardiovascular disease, uncontrolled psychiatric conditions, or severe liver impairment, and it should be avoided in those for whom a partial agonist is unsuitable.